BMRN
Biomarin Pharmaceutical Inc
NASDAQ: BMRN · HEALTHCARE · BIOTECHNOLOGY
$52.58
+0.53% today
Updated 2026-06-05
Market cap
$10.81B
P/E ratio
40.25
P/S ratio
3.34x
EPS (TTM)
$1.39
Dividend yield
—
52W range
$49 – $66
Volume
2.0M
Biomarin Pharmaceutical Inc (BMRN) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$52.58
12-Month target
$54.67
2030 Target
—
Intrinsic (DCF)
$175.57
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8B | $2.1B | $2.4B | $2.9B | $3.2B | $3.6B | $4.0B | $4.5B | $5.0B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 11.60% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 8.29%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.